Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006459 · ClinicalTrials.gov registry record · Phase 3
Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00006459 is a Phase 3 study of Breast Cancer that has completed, run by Eli Lilly and Company. The trial reports 20 study locations across 13 states.
The verdict
NCT00006459, a Phase 3 study of Breast Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if paclitaxel is more effective with or without gemcitabine for advanced breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel with or without gemcitabine in treating women who have advanced breast cancer.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG gemcitabine hydrochloride
Study Locations (20)
California
- Pacific Coast Hematology/Oncology Medical Group - Fountain Valley
- Office of Alex J.P. Makalinao - Los Angeles
- Hematology/Oncology Group - Santa Rosa
Florida
- Comprehensive Cancer Care Specialists of Boca Raton - Boca Raton
- Mercy Hospital - Miami
Illinois
- Memorial Medical Center - Springfield
- Carle Cancer Center - Urbana
Indiana
- Indiana Community Cancer Care, Inc. - Indianapolis
- Cancer Health Associates - Michigan City
New Jersey
- APN-IMPATH Research Corporation - Fort Lee
- Overlook Hospital - Summit
New York
- HemOnCare, P.C. - Brooklyn
- Interlakes Oncology/Hematology PC - Rochester
Alabama
- Comprehensive Cancer Institute of Huntsville - Huntsville
Arkansas
- Little Rock Hematology-Oncology Associates - Little Rock
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006459
The ClinicalTrials.gov registry entry for NCT00006459 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00006459 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00006459 about?
NCT00006459 is a clinical study titled "Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if paclitaxel is more effective with or without gemcitabine for advanced breast cancer. PURPOSE: Random...
What is the current status of trial NCT00006459?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-07. Estimated completion is 2005-10.
What conditions does trial NCT00006459 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00006459?
The interventions under investigation include: paclitaxel (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006459?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006459 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.